340B covered entities are exploring buying health insurance for patients at risk of contracting HIV in response to a huge reimbursement cut due to start in January for Gilead pre-exposure prophylaxis (PrEP) medications.
Gilead announced in April that, effective Jan. 1., it will reduce reimbursement for 340B pharmacies for its PrEP drugs Truvada and Descovy that uninsured patients get for free through the company’s Advancing Access patient assistance/medication assistance program. The new rate will be acquisition cost plus an $80 administrative fee and a $2.75 dispensing fee, compared with current reimbursement by Gilead at full retail price.
340B covered entities are exploring buying health insurance for patients at risk of contracting HIV in response to a huge reimbursement cut due to start in January for Gilead pre-exposure prophylaxis (PrEP) medications.
Please Login or Become a Paid Subscriber to View this Content
If you are already a paid subscriber, please follow the steps below.
